🆕 Clinical Year in Review at #ACR25 By Dr. Bryant England @unmc.bsky.social 🔶 Review the most impactful studies in #Rheumatology from the past year! ❓ Any studies you would add to the list? #RheumSky #MedSky #YearInReview

Acute and chronic viral infections, including Herpes Zoster (Shingles), Hepatitis C, HIV, CMV, influenza, and SARS-CoV-2, are linked with a substantial increased risk of cardiovascular events, from a systematic review. Figure for SARS-CoV-2 below newsroom.heart.org/news/some-ac...

🆕 Secrets & Pearls of #Rheumatology at #ACR25 | Part 1 by Dr. Janet Pope 🖐️ Cutaneous Pathology SLE/DM 🧴 Tips for SLE  💪 Cancer Screening in Myositis 🩸 Laboratory Testing 🥶 Raynaud's / Scleroderma 👀 Sjogrens Disease #RheumSky #MedSky #Lupus #Myositis #Scleroderma #Sjogrens

#ACR25 - Wednesday orals 🌟 Spondyloarthritis (mostly PsA) abstracts

#ACR25 - Monday orals 🌟 3:00pm CT - Disparities abstracts

#ACR25 - Tuesday orals 🌟 3:00pm CT - Osteoarthritis (OA) abstracts

#ACR25 - Monday posters 🌟 Crystals (gout, CPPD) abstracts

#ACR25: @jyazdanymd.bsky.social chief of rheumatology at San Francisco General Hospital @ucsanfrancisco.bsky.social#ACR25at the 2025 ACR Convergence, as part of session, “The Great Debate in AI: Unlocking Potential or Unleashing Chaos?” Image & quote taken by Larry Luxner #RareDisease #RheumSky #MedSky

#ACR25: Jeff Curtis, MD, professor of medicine at UAB, speaking at the 2025 ACR Convergence in Chicago as part of a session titled “The Great Debate in AI: Unlocking Potential or Unleashing Chaos?” Image & quote taken by, Larry Luxner #RareDisease #Rheumatology #AI #MedTech #RheumSky

Malignancy association with Ro52 positivity. #ACR25

jamanetwork.com/journals/jam... Another GLP-1 target: Age related macular degeneration

FDA Approves Obinutuzumab for Active Lupus Nephritis The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis. buff.ly/my15Pnn

What do rheumatologists & hematologists need to know about Castleman disease? In our NEWEST episode, we unpack diagnosis, treatment, & the evolving understanding of this complex condition LISTEN NOW🎙️→ acr.tw/48lersf

An editorial on the paper from @dfeterman.bsky.social & @alisonbays.bsky.social examining the impact of insurance prior authorizations on individuals with giant cell arteritis (risk of blindness if not treated) in WA state Thank you to @jrheumatol.bsky.social for publishing & highlighting

Local immune effector cell-associated toxicity syndrome (LICATS) in #CART-cell treated patients with autoimmune disease: an observational study - The Lancet Rheumatology www.thelancet.com/journals/lan...

Trial of metformin for knee #osteoarthritis showed improvement in knee pain vs. placebo. What’s the mechanism? Curious to see what the weight loss differences were been groups. jamanetwork.com/journals/jam...

Tolebrutinib is a BTK inhibitor that is being studied for the treatment of relapsing multiple sclerosis. Research findings from the GEMINI 1 and GEMINI 2 trials comparing tolebrutinib with teriflunomide are summarized in a new Quick Take video. nej.md/3S1hY5N #MedSky #NeuroSky

single-centre study of 469 consecutive RA pts - 15 had VTE (3%). Strongest risk factor of VTE was the history of previous VTE (OR 44.7), recent hospitalisation (OR 6.82), diabetes (OR 11.23), and JAKi (OR 5.54) (Other studies show inflammation incr VTE risk) pubmed.ncbi.nlm.nih.gov/40314997/

Inclusion of results from new large RCTs provides further robust evidence that the addition of low-dose colchicine to standard-of-care therapy decreases the incidence of MACE, MI, ischaemic stroke, & recurrent coronary revascularization in vascular disease patients academic.oup.com/eurheartj/ad...

Adding Acrometastases to synovitis differential 🤯

ICYMI: New content online:

Glucagon-like peptide-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer: an observational, retrospective cohort study - eClinicalMedicine www.thelancet.com/journals/ecl...

The SPARTAN Review Course is on! Dr. Aki Nakamura presented on the pathogenesis of axial spondyloarthritis, highlighting new science around HLA-B27, arthritogenic peptides and mechanisms of disease independent of HLA-B27. deptmed.queensu.ca/index.php/pe...

A major paper @nature.com this week found a significant decline in dementia after an outdated Shingles vaccine. I've reviewed the study and many other relevant ones here erictopol.substack.com/p/the-shingl...

A Phase 3 Trial of #Upadacitinib for Giant-Cell Arteritis | NEJM www.nejm.org/doi/full/10.... “In patients with giant-cell #arteritis, upadacitinib at a dose of 15 mg — but not 7.5 mg — with a 26-week glucocorticoid taper showed efficacy superior to that of placebo.” #Rheumsky #GCA

💫 Check out the new Rheum Madness x Rheum One Pagers bracket infographic! 🎉🏀📟 📖 Read most pivotal, innovative studies in #rheum in past 2 yrs 🎙️ Listen to the Rheum Madness podcasts 🏀 Submit Brackets before April 1 @rheummadness.bsky.social @davidleverenz.bsky.social @larneson.bsky.social

Very Early #SystemicSclerosis #Scleroderma #Rheumsky

Several BC Patients contributed to this. Thank you #Scleroderma

Abbvie gets European green light 🚥 for UPA in treatment of GCA

Selective mutation of Traf1/cIAP2 (V196) interaction attenuates inflammatory responses that may contribute to rheumatoid arthritis activity. THis may lead to a new class of therapies for RA

Today marks the start of #NationalKidneyMonth! 💜 This March, we’re raising awareness about lupus-related kidney disease & its impact on those living with #lupus. Help spread the word! Check out our blog to download the checklist & share it with friends & family to raise awareness: buff.ly/4bjjQPU

🌍💜 Today is Rare Disease Day! 🌍💜In honor of Rare Disease Day 2025, RDI’s team will light up four landmarks, to symbolize our support to people living with a rare disease worldwide. ✨ Stay tuned and watch as these landmarks light up from 7 PM CET tonight! #LightUpForRare #RareDiseaseDay

Cross-trait study of >300K patients’ electronic health records at UCSF and Stanford. Autoimmune conditions associate with greater Alzheimer’s risk (ORs 1.4–1.7). Women with autoimmune disorders have higher risk than men with autoimmune disorders

With the tragic news of a measles-related death in Texas, it is important to remember that we also have a measles outbreak in Canada, with the vast majority of cases among unvaccinated individuals. Ontario data below 👇

Day 1 at #ASM2025 in Calgary! The Journal of Rheumatology is proud to support Canadian rheumatology research and its impact on a global scale. Our longstanding partnership with the Canadian Rheumatology Association strengthens the future of rheumatology. Looking forward to insightful discussions!

ACPA+ linked to nodule progression. 208 #RA pts w/ Chest CT studied. Lung nodules seen on 1st CT in 10% before RA Dx (10.4 mos before). Positive ACPA (not RF) was assoc w/ nodule progression (OR 3.69). csDMARDs & b/ts-DMARDs NO affect on nodule progression.

The German case series: ➡️CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series - The Lancet Rheumatology www.thelancet.com/journals/lan...

Predictors of response to intravenous #immunoglobulin in patients with #dermatomyositis: the ProDERM study 💉IVIg was effective regardless of demographic features and #autoantibody status. 💉Higher cutaneous activity and/or #anti-TIF1-γ responded better academic.oup.com/rheumatology...

#CAR-T #SystemicSclerosis #scleroderma #rheumsky

Dr. E. Volksmann Histopathology correlation with functional imaging and tracer signal in ILD #RWCS2025 #RA #ILD

Absolutely crazy 🤦🏻‍♀️ bsky.app/profile/roxa...

Use HRCT to screen for #SSc #ILD PFTs can miss early disease #RWCS2025 #Scleroderma #SystemicSclerosis

The concept of difficult-to-treat disease in rheumatology: where next? - The Lancet Rheumatology www.thelancet.com/journals/lan...

#CAR-T cell therapies, a timeline #RWCS2025 Dr. A. Postolova

#Secukinumab continues to show efficacy in GCA Hopefully phase III will show the same 🤞🏼 Dr. A. Dua vasculitis presentation at #RWCS2025